157. Sturge-Weber syndrome Clinical trials / Disease details

Clinical trials : 10 / Drugs : 13 - (DrugBank : 4) / Drug target genes : 5 - Drug target pathways : 63

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03047980 (ClinicalTrials.gov)	January 2017	2/2/2017	Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome	Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome	Sturge-Weber Syndrome	Drug: Sirolimus	Anne Comi, MD	Children's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	3 Years	31 Years	All	10	Phase 2/Phase 3	United States
2	NCT02080624 (ClinicalTrials.gov)	January 2011	18/4/2013	Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome	Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome.	Sturge- Weber Syndrome	Drug: Drug: Topical Rapamycin	Clinica Universidad de Navarra, Universidad de Navarra	NULL	Completed	16 Years	65 Years	Both	23	Phase 2	Spain